Browse studies

Find your next paid study

8 recruiting studies matching your filters

Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome

Background: \- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or conne…

Li-Fraumeni SyndromeNeoplasmsTp53 Mutations

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT01443468

Phase 2

A Phase 2 Trial of Maintenance Abemaciclib/Letrozole After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wildtype Endometrial Cancer

The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positi…

Endometrial CancerRecurrent Endometrial CancerTP53

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06366347

Registry Study of Children and Adults Patients With Relapsed, Refractory, or Progressive Sonic Hedgehog Medulloblastoma Harboring U1 Mutation

The purpose of this study is to create a biobank for patients diagnosed with Sonic Hedgehog Medulloblastoma at Baylor College of Medicine/Texas Children's Canc…

Medulloblastoma RecurrentMedulloblastoma, Childhood, RecurrentMedulloblastoma, SHH-activated and TP53 Mutant+1 more

Estimated

~$10 – $1,125

Mohammad H. Abu ArjaNCT07242963

Phase 1

A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced …

TP53 Y220C MutationAdvanced Solid Tumors

Estimated

~$10 – $8,750

PMV Pharmaceuticals, IncNCT07372625

Phase 1

HM2024-29: Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabi…

Acute Myeloid LeukemiaTP53

Estimated

~$10 – $6,250

Masonic Cancer Center, University of MinnesotaNCT07008638

Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk c…

Li-Fraumeni SyndromeTP53 Gene MutationHereditary Cancer Syndrome+2 more

Estimated

~$10 – $1,125

Dana-Farber Cancer InstituteNCT04541654

Phase 2

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for c…

Hematologic MalignancyAcute LeukemiaRemission+21 more

Estimated

~$10 – $6,250

Masonic Cancer Center, University of Minnesota

Phase 1

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients

Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients

Acute Myeloid LeukemiaTP53 Gene Mutation

Estimated

~$10 – $6,250

Northside Hospital, Inc.NCT07511062